TechSeeker Profile

Medimmune Inc
Profile last edited on: 10/14/2016

NO Business Identifier is currently available for this company.
TS Type
Mid-size Corporation
Status
Acquired
Year Founded
1988
Last Involved Year
2018

Key People / Management

Location Information

One Medimmune Way
Gaithersburg, MD 20878
   (301) 398-0000
   www.medimmune.com

Public Profile

In June 2007 Medimmune Inc was acquired by AstraZeneca. MedImmune develops drugs for transplants and infectious diseases. Its product-development strategy emphasizes prevention over treatment. Products include CytoGam, which prevents and treats cytomegalovirus disease in organ transplant patients, and RespiGam (an intravenous treatment ), which prevents respiratory syncytial virus (RSV), a leading cause of pneumonia and bronchiolitis in infants. MedImmune has received FDA approval to market Synagis (an injectable treatment for RSV). Products in development include vaccines to prevent genital warts, cervical cancer, Lyme disease, urinary tract infections, and organ transplant rejection. The firm is buying U.S. Bioscience to move into the oncology drug market. Manufactures the vaccine nasal spray FluMist(tm)

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
USA
Employment
2,059
Revenue
N/A
Public/Private
Publicly Traded
Stock Info
NASDAQ : MEDI
Received SBIR $$
Yes